A Study of Azenosertib (ZN-c3) in Combination With Gemcitabine in Subjects With Osteosarcoma
Phase 1/2 Completed
31 enrolled
BREGO
Phase 1/2 Completed
66 enrolled
LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
Phase 1/2 Completed
51 enrolled
GEMMK
Phase 1/2 Completed
25 enrolled 15 charts
Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
Phase 1/2 Completed
272 enrolled
Morpheus Lung
Phase 1/2 Completed
314 enrolled
A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)
Phase 1/2 Completed
341 enrolled 28 charts
TRESR
Phase 1/2 Completed
276 enrolled 33 charts
A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors
Phase 1/2 Completed
332 enrolled 44 charts
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2 Completed
3 enrolled 10 charts
Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy
Phase 1/2 Completed
89 enrolled 21 charts
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
Phase 1/2 Completed
83 enrolled 14 charts
LAPTOP
Phase 1/2 Completed
55 enrolled
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
64 enrolled 13 charts
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
Phase 1/2 Completed
119 enrolled 24 charts
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
CANFOUR
Phase 1/2 Completed
167 enrolled
SCALOP-2
Phase 1/2 Completed
159 enrolled
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Phase 1/2 Completed
13 enrolled 17 charts
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
33 enrolled 14 charts
A Trial of SHR-1701 in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Pancreatic Cancer
Phase 1/2 Completed
56 enrolled
A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation
Phase 1/2 Completed
93 enrolled 24 charts
Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer
Phase 1/2 Completed
15 enrolled 13 charts
MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.
Phase 1/2 Completed
213 enrolled 42 charts
M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)
Phase 1/2 Completed
70 enrolled 17 charts
AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
34 enrolled
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic Cancer
Phase 1/2 Completed
47 enrolled 22 charts
A Phase 1/2 Study of CAN04 in Combination With Different Chemotherapy Regimens in Subjects With Advanced Solid Tumors
Phase 1/2 Completed
40 enrolled
A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects
Phase 1/2 Completed
153 enrolled
Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer
Phase 1/2 Completed
7 enrolled
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
Phase 1/2 Completed
8 enrolled 9 charts
AA NABPLAGEM
Phase 1/2 Completed
27 enrolled
A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Phase 1/2 Completed
37 enrolled 16 charts
ALPINE
Phase 1/2 Completed
217 enrolled 18 charts
A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Phase 1/2 Completed
26 enrolled
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Phase 1/2 Completed
70 enrolled 17 charts
GemTax
Phase 1/2 Completed
37 enrolled 17 charts
LENAGEM
Phase 1/2 Completed
34 enrolled
A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer
Phase 1/2 Completed
184 enrolled 22 charts
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
Phase 1/2 Completed
28 enrolled
S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery
Phase 1/2 Completed
134 enrolled 12 charts
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 1/2 Completed
26 enrolled 13 charts
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1/2 Completed
46 enrolled 18 charts
Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma
Phase 1/2 Completed
127 enrolled
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Phase 1/2 Completed
21 enrolled 11 charts
BeGeRN
Phase 1/2 Completed
30 enrolled
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Phase 1/2 Completed
18 enrolled 15 charts
CheckMate370
Phase 1/2 Completed
341 enrolled 28 charts
Sorafenib, Gemcitabine, and Capecitabine in Treating Patients With Unresectable and/or Metastatic Kidney Cancer
Phase 1/2 Completed
17 enrolled 13 charts
MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer
Phase 1/2 Completed
81 enrolled 19 charts